|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists |
Nov 2024 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
Dec 2020 |
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
Nov 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
T-cell dysfunctions in myelodysplastic syndromes |
Apr 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Nov 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
